All In Biotech

Drug Trial Radar · NCT00137995

R-ICE Versus R-DHAP in Patients Aged 18-65 With Relapse Diffuse Large B-cell Lymphoma

Randomized Study of ICE Plus RITUXIMAB Versus DHAP Plus Rituximab in Previously Treated Patients With Diffuse Large B-cell Lymphoma, Followed by Randomized Maintenance With Rituximab

Last checked: Nov 20, 2026Latest source record: Aug 28, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 481 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

481

Actual

Start

Jun 2003

Primary completion

Oct 2008

Study completion Oct 2008

Sponsor

Lead sponsor
Lymphoma Study AssociationAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 30, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the efficacy and safety of induction therapy R-ICE in comparison to R-DHAP after 3 cycles adjusted to successful mobilization of stem cells in patients with previously treated diffuse large B-cell lymphoma CD20. The goal is to detect a difference in mobilization adjusted response rate of 15% between R-ICE and R-DHAP. The other objective is to evaluate the efficacy and safety of MabThera maintenance therapy after transplantation as measured by the event free survival. The goal is to obtain a 15% increase of event free survival at 2 years.

Conditions

  • Lymphoma, Large-Cell, Diffuse

Interventions

  • RituximabDrug

    375 mg/m² D-2/D1

  • EtoposideDrug

    100 mg/m² D1-D2-D3

  • CarboplatineDrug

    max 800mg D2

  • Ifosfamide + MesnaDrug

    5 g/m² from D2 to D13

  • CisplatineDrug

    100 mg/m² from D1 to D13

  • Cytosine ArabinosideDrug

    2000 mg/m²/12 h D2 D3

  • DexamethasoneDrug

    40 mg From D1 to D4

  • Autologous Stem Cell TransplantationProcedure

  • BCNUDrug

    300mg/m² on D-6

  • EtoposideDrug

    200 mg/m² from D-6 to D-3

  • CytarabineDrug

    100 mg/m² from D-6 to D-3

  • MelphalanDrug

    140 mg/m² on D-2

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. MARR (mobilization adjusted response rate)Time frame: 3 months
  2. EFS (event free survival)Time frame: 2 years post transplantation

Locations

10 sites in 10 countries. Site status is shown where the registry gives one.

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Australian leukemia and lymphoma group

    Sydney, Australia

  • Groupe d'atude des lymphome de l'adulte

    Yvoir, Belgium

  • Czech Lymphoma study group

    Prague, Czechia

  • Hospital district of south west Finland

    Turku, Finland

  • German high grade non hodgkin's lymphoma group

    Hamburg, Germany

  • Israel Society of Hematology

    Tel HaShomer, Israel

  • Nordic center

    Uppsala, Sweden

  • Schweirische Arbeitsgruppe fur klinische Krebsforschung

    Lausanne, Switzerland

  • National cancer research institute

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.